1 unchanged sentence
Issuer Purchases of Equity Securities
−Removed: The following table provides information about Cigna's share repurchase activity for the quarter ended June 30, 2022:
+Added: The following table provides information about Cigna's share repurchase activity for the quarter ended September 30, 2022:
Period Total # of shares purchased (1)
5 unchanged sentences
of publicly announced program (3)
−Removed: April 1-30, 2022 1,519,764 $ 253.80 1,517,385 $ 9,444,290,632
−Removed: May 1-31, 2022 1,605,175 $ 260.50 1,604,582 $ 9,026,293,505
−Removed: June 1-30, 2022 793,253 $ 256.02 792,733 $ 8,823,335,866
+Added: July 1-31, 2022 10,450,133 (1) 10,446,592 $ 5,323,335,866
+Added: August 1-31, 2022 557 $ 294.64 — $ 5,323,335,866
+Added: September 1-30, 2022 1,479 $ 284.43 — $ 5,323,335,866
Total 10,452,169 (1) 10,446,592 N/A
1 unchanged sentence
1) payment of taxes on vesting of restricted stock (grants and units) and strategic performance shares and 2) payment of the exercise price and taxes for certain stock options exercised.
−Removed: Employees tendered 2,379 shares in April, 593 shares in May and 520 shares in June 2022.
+Added: Employees tendered 3,541 shares in July, 557 shares in August and 1,479 shares in September 2022.
+Added: Amount purchased in July 2022 also reflects the initial delivery of 10.4 million shares pursuant to the ASR agreements discussed in the Liquidity and Capital Resources section of Management's Discussion and Analysis of Financial Condition and Results of Operations in Part I, Item 2.
+Added: Such repurchase was made pursuant to the Company's share repurchase program described in note (2) below.
+Added: Average price paid per share for the period July 1 - July 31, 2022 for shares not purchased pursuant to the ASR agreements was $270.27.
(2) Additionally, the Company maintains a share repurchase program authorized by the Board of Directors.
3 unchanged sentences
The program may be suspended or discontinued at any time and does not have an expiration date.
−Removed: From July 1, 2022 through August 3, 2022, we repurchased 10.4 million shares through the initial delivery under the ASR agreements discussed in the Liquidity and Capital Resources section of Management's Discussion and Analysis of Financial Condition and Results of Operations in Part I, Item 2.
+Added: From October 1, 2022 through November 2, 2022, we did not repurchase shares except for the 1.9 million shares we expect to receive as final settlement of the ASR agreements discussed in the Liquidity and Capital Resources section of Management's Discussion and Analysis of Financial Condition and Results of Operations in Part I, Item 2 of this Quarterly Report on Form 10-Q.
+Added: The total number of shares of our common stock repurchased under the ASR agreements is expected to be 12.3 million.
Such repurchases were made pursuant to the Company's share repurchase program described above.
−Removed: Share repurchase authority was $5.3 billion as of August 3, 2022.
+Added: Share repurchase authority was $5.3 billion as of November 2, 2022.
(3) Approximate dollar value of shares is as of the last date of the applicable month.
−Removed: INDEX TO EXHIBITS
−Removed: Number Description Method of Filing
−Removed: 10.1 Revolving Credit and Letter of Credit Agreement, dated as of April 28, 2022 , with the banks named therein, JPMorgan Chase Bank, N.A., as administrative agent, BofA Securities, Inc., Citibank, N.A., Morgan Stanley Senior Funding, Inc., MUFG Bank, LTD and Wells Fargo Securities, LLC, as joint lead arrangers and joint bookrunners
−Removed: Filed by the registrant as Exhibit 10.1 to the Current Report on Form 8-K on April 29, 2022 and incorporated herein by reference.
−Removed: 31.1 Certification of Chief Executive Officer of Cigna Corporation pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934
−Removed: Filed herewith.
−Removed: 31.2 Certification of Chief Financial Officer of Cigna Corporation pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934
−Removed: Filed herewith.
−Removed: 32.1 Certification of Chief Executive Officer of Cigna Corporation pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C.
−Removed: Furnished herewith.
−Removed: 32.2 Certification of Chief Financial Officer of Cigna Corporation pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C.
−Removed: Furnished herewith.
−Removed: 101 The following materials from Cigna Corporation's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in inline XBRL (eXtensible Business Reporting Language):
−Removed: (i) the Consolidated Statements of Income;
−Removed: (ii) the Consolidated Statements of Comprehensive Income;
−Removed: (iii) the Consolidated Balance Sheets;
−Removed: (iv) the Consolidated Statements of Total Equity;
−Removed: (v) the Consolidated Statements of Cash Flows;
−Removed: and (vi) the Notes to the Consolidated Financial Statements
−Removed: Filed herewith.
−Removed: 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) Filed herewith.
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: August 4, 2022
−Removed: CIGNA CORPORATION
−Removed: Executive Vice President and
−Removed: Chief Financial Officer
−Removed: (Principal Financial Officer and Authorized Signatory)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.